References (click to expand)

1. Villavicencio J, Allen RH. Unscheduled bleeding and contraceptive choice: increasing satisfaction and continuation rates. Open Acc J Contracept. 2016;7:43-52. doi: 10.2147/OAJC.S85565
2. Slynd [package insert]. Exeltis USA, Inc.; Florham Park, NJ; 2019.
3. Data on file. Exeltis USA, Inc.; Florham Park, NJ; 2019.
4. Fuhrmann U, Krattenmacher R, Slater ED, et al. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception. 1996;54(4):243-251
5. Regidor PA, Schindler AE. Antiandrogenic and antimineralocorticoid health benefits of COC containing newer progestins: dienogest and drospirenone. Oncotarget. 2017:8 (47): 83334-83342.
6. Vroonen L, Cavalier E, Vranken L, et al. Influence of drospirenone on renin-angiotensin-aldosterone system evaluation. Endocrine Abstracts. 2011;26:12.
7. Slopien R, Milewska E, Rynio P, et al. Use of oral contraceptives for management of acne vulgaris and hirsutism in women of reproductive and late reproductive age. Menopause Review. 2018;17(1):1-4. doi: 10.5114/pm.2018.74895
8. Greer JB, Modugno F, Allen G, et al. Androgenic progestins in oral contraceptives and the risk of epithelial ovarian cancer. Obstet Gynecol. 2005;105:731-740.
9. Batur P. Female contraception. Cleveland Clinic Center for Continuing Education. Published December 2016.
10. Glisic M, Shahzad S, Tsoli S, et al. Association between progestin-only contraceptive use and cardiometabolic outcomes: a systematic review and meta-analysis Eur J Prev Cardiol. 2018;25(10):1042-1052. doi: 10.1177/2047487318774847.
11. Duijkers IJM, Heger-Mahn D, Drouin D, et al. Maintenance of ovulation inhibition with a new progestogen-only pill containing drospirenone after scheduled 24-h delays in pill intake. Contraception. 2016:93(4): 303-309.

Bitnami